SIMULATIONS PLUS INC.
139.25
USD
(+0.15%)
04/29/2025 - 09:00
Closed 15 min delayed data - NASDAQ Stocks
| Open: | 139.25 |
| Change: | +0.21 |
| Volume: | 12 |
| Low: | 139.25 |
| High: | 139.25 |
| High / Low range: | 0 |
| Type: | Stocks |
| Ticker: | SLP |
| ISIN: |
SIMULATIONS PLUS INC. news, videos and press releases
For more news please use our advanced search feature.
SIMULATIONS PLUS INC. - More news...
SIMULATIONS PLUS INC. - More news...
- 04/21/2025 - 11:50 Simulations Plus Supports New FDA Roadmap for Reducing Animal Testing in Preclinical Safety Studies
- 04/03/2025 - 20:05 Simulations Plus Reports Second Quarter Fiscal 2025 Financial Results
- 03/20/2025 - 11:00 Simulations Plus Announces Second Quarter Fiscal Year 2025 Earnings and Conference Call Date
- 03/10/2025 - 11:00 Simulations Plus to Present at the KeyBanc Capital Markets Virtual Healthcare Investor Forum
- 02/04/2025 - 12:30 Simulations Plus to Participate in Upcoming Healthcare Investor Conferences
- 01/22/2025 - 12:50 Simulations Plus and Enabling Technologies Consortium Announce Strategic Collaboration to Advance GastroPlus® Enhancements
- 01/13/2025 - 12:50 Simulations Plus Supported Development of Every FDA-Approved Drug in 2024
- 01/07/2025 - 21:06 Simulations Plus Reports First Quarter Fiscal 2025 Financial Results
- 12/17/2024 - 21:06 Simulations Plus Announces First Quarter Fiscal Year 2025 Earnings and Conference Call Date
- 11/19/2024 - 13:30 Simulations Plus to Participate in the BTIG Digital Health Forum
- 11/13/2024 - 13:30 Simulations Plus and the University of Connecticut Receive New FDA Grant to Expand Mechanistic Modeling Approaches for Long-Acting Injectables
- 08/15/2023 - 12:30 Researchers Use the Simulations Plus DILIsym® Platform to Predict Safety of Combined CBD and VPA Treatment
- 07/13/2023 - 12:30 Simulations Plus Releases ADMET Predictor® 11
- 07/06/2023 - 20:06 Simulations Plus Reports Third Quarter Fiscal 2023 Financial Results
- 06/21/2023 - 20:06 Simulations Plus Announces Third Quarter Fiscal Year 2023 Earnings and Conference Call Date
- 06/20/2023 - 12:00 Simulations Plus Acquires Immunetrics to Expand its Immunology and Oncology Drug Development Capabilities
- 05/10/2023 - 12:30 Simulations Plus Launches New Integrated Pulmonary Software and Services Package to Streamline Drug Development and Improve Patient Outcomes
- 04/18/2023 - 12:30 Simulations Plus Receives U.S. FDA Renewal for DILIsym Software Licenses
- 04/05/2023 - 20:06 Simulations Plus Reports Second Quarter Fiscal 2023 Financial Results
- 03/30/2023 - 12:30 MIDD+ 2023 Panelists Discuss How to Increase Gender Equity for Women in Science
- 03/28/2023 - 12:30 Simulations Plus Enters New Strategic Collaboration to Discover Anticancer Therapies Through Its AI-Driven Drug Design Technology
- 03/21/2023 - 20:06 Simulations Plus Sets Date for Second Quarter Fiscal Year 2023 Earnings Release and Conference Call
- 03/16/2023 - 12:30 Simulations Plus to Present at Sidoti March Small-Cap Conference
- 03/15/2023 - 12:30 Simulations Plus Enters Partnership to Apply AI/ML Technologies to Design Novel Compounds
- 03/09/2023 - 13:30 Lixoft Adds New Data Formatting and Reporting Modules to MonolixSuite™ in Version 2023R1
- 03/07/2023 - 13:30 Simulations Plus to Present at Oppenheimer 33rd Annual Healthcare Conference
- 02/28/2023 - 13:30 Simulations Plus to Present at Raymond James 44th Annual Institutional Investors Conference
- 02/16/2023 - 13:30 Simulations Plus and Global Agrochemicals Leader to Collaborate on Machine Learning Models
- 02/09/2023 - 13:30 Simulations Plus Releases Redesigned NAFLDsym® QSP Software Tool
- 01/12/2023 - 13:30 Simulations Plus Releases DILIsym X (DSX) Beta with Redesigned Software Infrastructure
